| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/04/2011 | US7862828 Allergy vaccines containing hybrid polypeptides |
| 01/04/2011 | US7862824 Enhancement of GLP-2 activity of suppressing appetite |
| 01/04/2011 | CA2640591C Use of 5-ht5-ligands in the treatment of neurodegenerative and neuropsychiatric disturbances |
| 01/04/2011 | CA2481754C Antibiotic/benzoyl peroxide dispenser |
| 01/04/2011 | CA2474343C Nsaid-containing topical formulations that demonstrate chemopreventive activity |
| 01/04/2011 | CA2458533C Imidazole derivates as anti-inflammatory agents |
| 01/04/2011 | CA2447335C Targeted delivery of drugs for the treatment of viral infections |
| 01/04/2011 | CA2446828C Adenosine a1 receptor antagonists for treating hypoxia-induced learning and memory impairment |
| 01/04/2011 | CA2429312C Novel pyridine-substituted pyrazolopyridine derivatives |
| 01/04/2011 | CA2412941C Piperidine compounds for use as ccr-3 inhibitors |
| 01/04/2011 | CA2408754C Delivery devices for treatment of vascular disease |
| 01/04/2011 | CA2400959C Composition for the prevention and/or treatment of vascular diseases, comprising propionyl l-carnitine and coenzyme q10 |
| 01/04/2011 | CA2389544C Compositions and methods for double-targeting virus infections and targeting cancer cells |
| 01/04/2011 | CA2382848C Diagnostics and therapeutics for osteoporosis |
| 01/04/2011 | CA2380370C Novel derivatives of dicarboxylic acid having pharmaceutical properties |
| 01/04/2011 | CA2354154C A.beta.-peptide screening assay |
| 01/04/2011 | CA2352005C Extracts, compounds & pharmaceutical compositions having anti-diabetic activity and their use |
| 01/04/2011 | CA2341239C A preventive or therapeutic agent for pancreatitis comprising il-6 antagonist as an active ingredient |
| 01/04/2011 | CA2319672C Compounds and compositions for delivering active agents |
| 01/04/2011 | CA2317505C Enzyme catalyzed therapeutic agents |
| 01/04/2011 | CA2306875C Nutritional supplement for cerebral metabolic insufficiencies |
| 01/04/2011 | CA2246744C Immunomodulatory complex and use thereof in diseases caused by helicobacter |
| 01/04/2011 | CA2239208C Treatment and diagnosis of infections due to helicobacter pylori |
| 01/04/2011 | CA2217191C Pharmaceutical composition containing pectin and a phospholipid, used as an antidiarrheal and antiulcer agent |
| 01/04/2011 | CA2163439C Methods of using bcl-2 for the therapeutic treatment and prevention of diseases |
| 12/30/2010 | US20100331423 Aqueous solution of olanexidine, method of preparing the aqueous solution, and disinfectant |
| 12/30/2010 | US20100331414 Crystal comprising (2r)-2-propyloctanoic acid and amine |
| 12/30/2010 | US20100331251 Polypeptides homologous to vegf and bmp1 |
| 12/30/2010 | US20100330673 Methods of making enhanced, autologous fat grafts |
| 12/30/2010 | US20100330613 Methods for determining efficacy of chemotherapeutic agents |
| 12/30/2010 | US20100330554 Diagnostic kit for solid cancer and medicament for solid cancer therapy |
| 12/30/2010 | US20100330198 Aminosugar, glycosaminoglycan, and s-adenosylmethionine composition for the treatment and repair of connective tissue |
| 12/30/2010 | US20100330186 Medicaments for inhalation comprising an anticholinergic and a betamimetic |
| 12/30/2010 | US20100330184 Injection vehicle for polymer-based formulations |
| 12/30/2010 | US20100330164 Method of increasing tear production with purinergic receptor agonists |
| 12/30/2010 | US20100330044 Mesp1 as a master regulator of multipotent cardiovascular progenitor specification and uses thereof |
| 12/30/2010 | US20100330037 Adenoviral systems and the uses thereof |
| 12/30/2010 | US20100329984 Respiratory dispersion for metered dose inhalers |
| 12/30/2010 | US20100329976 Nanoparticulate compositions of angiogenesis inhibitors |
| 12/29/2010 | WO2010151488A1 Combination of boceprevir with 5- ( { 6- [2, 4- bis (trifluoromethyl) phenyl] pyridazin-3 -yl } methyl) -2- (2 -fluorophenyl) -5h- imidazo [4, 5-c] pyridine for the treatment of hcv |
| 12/29/2010 | WO2010151487A1 Combination of telaprevir with 5- ({6- [2,4-bis (trifluoromethyl) phenyl] pyridazin-3 -yl)methyl) -2- (2 -fluorophenyl) -5h- imidazo [4, 5-c]pyridine for the treatment of hcv |
| 12/29/2010 | WO2010151472A1 Combination of a ns5b polymerase inhibitor and a hcv ns3 protease inhibitor for the treatment of hcv |
| 12/29/2010 | WO2010150819A1 Therapeutic agent for ischemic cerebrovascular disorders |
| 12/29/2010 | WO2010150014A1 5r- 5 -deuterated glitazones for respiratory disease treatment |
| 12/29/2010 | WO2010149772A1 Preparation comprising insulin, nicotinamide and an amino acid |
| 12/29/2010 | WO2010149596A1 Compositions for treating degenerative joint diseases |
| 12/29/2010 | WO2010149394A1 Combination treatment op a g2 checkpoint inhibitor (sb-218078) and a chemotherapeutic agent for tumorigenic cells in solid tumors |
| 12/29/2010 | WO2010149273A1 Pharmaceutical composition for emergency contraception |
| 12/29/2010 | WO2010148572A1 Method for treating or ameliorating mucocutaneous or ocular toxicities |
| 12/29/2010 | EP2267454A2 Diagnosis and prevention of cancer cell invasion |
| 12/29/2010 | EP2267445A1 Methods of detecting small intestinal bacterial overgrowth (SIBO) in a human subject |
| 12/29/2010 | EP2267431A2 Gas sensor |
| 12/29/2010 | EP2267117A2 Differentiation modulating agents and uses therefor |
| 12/29/2010 | EP2266665A1 Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| 12/29/2010 | EP2266628A2 Method of determining the susceptibility to bone meatastases by EPhA2 expression |
| 12/29/2010 | EP2266624A2 Duramycin peptide binding to anionic phospholipids and aminophospholipids conjugates and their use in treating viral infections |
| 12/29/2010 | EP2266621A2 Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics |
| 12/29/2010 | EP2266620A2 Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics |
| 12/29/2010 | EP2266619A1 Pharmaceutical composition based on hepatoprotector and prebiotic, the production and use thereof |
| 12/29/2010 | EP2266607A2 Immunoconjugates for treating cancer |
| 12/29/2010 | EP2266590A2 Active agent delivery sytems and methods for protecting and administering active agents |
| 12/29/2010 | EP2266586A1 Compositions and method for alleviating inflammation and oxidative stress in a mammal |
| 12/29/2010 | EP2266584A2 Composition with strontium and vitamin D for the prophylaxis and/or treatment of cartilage and/or bone conditions |
| 12/29/2010 | EP2266582A1 Pharmaceutical composition for preventing dysbiosis associated with enteral administration of antibiotics |
| 12/29/2010 | EP2266581A1 Pharmaceutical composition of antibiotics and prebiotics for preventing and treating dysbiosis during antibacterial therapy |
| 12/29/2010 | EP2266576A1 Treatment of diabetes with thiazolidinedione and sulphonylurea |
| 12/29/2010 | EP2266574A1 Therapeutic use on-demand of formoterol and budesonide |
| 12/29/2010 | EP2266570A1 Use of binding partners for 5-HT5 receptors for treating neurodegenerative and neuropsychiatric disorders |
| 12/29/2010 | EP2266566A2 Nicotinamide derivatives and their use as therapeutic agents |
| 12/29/2010 | EP2266564A1 Pharmaceutical oral dosage form comprising a combination of an opioid agonist and an opioid antagonist |
| 12/29/2010 | EP2266561A2 IKK Inhibitors for the Treatment of Endometriosis |
| 12/29/2010 | EP2266559A1 Therapeutic agent for ophthalmic disease |
| 12/29/2010 | EP2266558A2 Treatment of neuropathic pain with N-methyl-D-aspartate (NMDA) receptor antagonists |
| 12/29/2010 | EP2266557A1 Method of utilization of combination of benzophenone derivative or salt thereof and immunosuppressing agent, and pharmaceutical composition comprising these components |
| 12/29/2010 | EP2266551A1 Compositions and kits comprising a defined boron compound and methods of their preparation |
| 12/29/2010 | EP2266550A1 Antagonists of ß-catenin for preventing and/or treating neurodegenerative disorders |
| 12/29/2010 | EP2266547A1 Composition for the transdermal delivery of fentanyl |
| 12/29/2010 | EP2266544A2 Method for encapsulating therapeutic substances in cells |
| 12/29/2010 | EP2266539A2 Methods of treatment using a gastric retained gabapentin dosage |
| 12/29/2010 | EP2266534A1 Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections |
| 12/29/2010 | EP2266502A1 Apparatus for stenting with enhanced protection against embolism, restenosis and thrombus formation |
| 12/29/2010 | EP2265263A2 Chewing composition and the use thereof |
| 12/29/2010 | EP2265258A2 Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| 12/29/2010 | EP2265257A2 Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| 12/29/2010 | EP1732575B1 Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions |
| 12/29/2010 | EP1529062B1 Therapeutic use of kremen 1 and 2, inhibitors of the canonical wnt-signal transduction |
| 12/29/2010 | EP1494705B1 A composition and method for killing of tumours |
| 12/29/2010 | EP1387673B1 Abuse-resistant controlled-release opioid dosage form |
| 12/29/2010 | EP1345611B1 An antibiotic/analgesic formulation and a method of making this formulation |
| 12/29/2010 | EP1286657B1 Nasal ointment based on white petroleum jelly |
| 12/29/2010 | EP1197209B1 Percutaneously absorbable preparations |
| 12/29/2010 | EP1183022B1 Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response |
| 12/29/2010 | EP1127069B1 Method of making a monomeric beta-form of a prion protein |
| 12/29/2010 | EP1077678B1 Mucoadhesive compositions for administration of biologically active agents to animal tissue |
| 12/29/2010 | CN1989439B Methods and compositions for the treatment of uveitis |
| 12/29/2010 | CN1976723B Use of preparing medicine for treating or preventing infectious diseases |
| 12/29/2010 | CN1968691B Composition for acceleration of alcohol metabolism or recuperation from fatigue through gluconeogenesis |
| 12/29/2010 | CN1935262B Use of red Nocardia cyto skeleton for preparing anti human papillomavirus medicine |
| 12/29/2010 | CN1901802B Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions |
| 12/29/2010 | CN1856504B Anti-infarction molecules |